Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × isatuximab × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 31 Recurrence 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Hematologic Neoplasms 2 Smoldering Multiple Myeloma 1 Renal Insufficiency 1 Purpura 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Nausea 1 Macroglossia 1 Lymphoproliferative Disorders 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoproliferative Disorders 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Hepatomegaly 1 Gastrointestinal Hemorrhage 1 Diarrhea 1 Constipation 1

Interventions

Cyclophosphamide 11 blinatumomab 8 fludarabine 7 venetoclax 6 fludarabine phosphate 5 Cytarabine 5 Rituximab 4 Lenalidomide 4 Dexamethasone 4 Blood Specimen Collection 4 Azacitidine 4 obinutuzumab 3 daratumumab 3 pembrolizumab 2 nilotinib 2 Vincristine 2 Radiotherapy 2 Methotrexate 2 Melphalan 2 Immunotherapy, Adoptive 2 Imatinib Mesylate 2 Idarubicin 2 Daunorubicin 2 Dasatinib 2 Chemotherapy, Adjuvant 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 tetrathiomolybdate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡